Israel Englander Kura Oncology, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 339,482 shares of KURA stock, worth $6.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

339,482

Previous 488,216 30.46%

Holding current value

$6.06 Million

Previous $10.4 Million 32.88%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$17.53 - $22.98 $2.61 Million - $3.42 Million	-148,734 Reduced 30.46%	339,482 $6.99 Million
Q1 2024 May 15, 2024	BUY	$13.42 - $23.53 $4.77 Million - $8.37 Million	355,726 Added 268.49%	488,216 $10.4 Million
Q4 2023 Feb 14, 2024	SELL	$7.58 - $14.38 $2 Million - $3.79 Million	-263,681 Reduced 66.56%	132,490 $1.91 Million
Q2 2023 Aug 14, 2023	BUY	$9.62 - $13.99 $3.61 Million - $5.25 Million	374,981 Added 1769.61%	396,171 $4.19 Million
Q1 2023 May 15, 2023	SELL	$10.71 - $14.6 $381,661 - $520,285	-35,636 Reduced 62.71%	21,190 $259,000
Q4 2022 Feb 14, 2023	SELL	$11.23 - $16.9 $4.58 Million - $6.89 Million	-407,629 Reduced 87.77%	56,826 $705,000
Q3 2022 Nov 14, 2022	BUY	$12.01 - $19.45 $4.82 Million - $7.81 Million	401,725 Added 640.4%	464,455 $6.34 Million
Q2 2022 Aug 15, 2022	SELL	$10.71 - $18.33 $998,889 - $1.71 Million	-93,267 Reduced 59.79%	62,730 $1.15 Million
Q1 2022 May 16, 2022	SELL	$11.78 - $16.98 $1.13 Million - $1.63 Million	-95,765 Reduced 38.04%	155,997 $2.51 Million
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $1.85 Million - $2.96 Million	151,149 Added 150.23%	251,762 $3.53 Million
Q3 2021 Nov 15, 2021	SELL	$15.42 - $21.72 $4.49 Million - $6.32 Million	-291,202 Reduced 74.32%	100,613 $1.88 Million
Q2 2021 Aug 16, 2021	BUY	$20.85 - $29.88 $1.39 Million - $1.99 Million	66,711 Added 20.52%	391,815 $8.17 Million
Q1 2021 May 17, 2021	BUY	$24.75 - $39.14 $2.9 Million - $4.59 Million	117,192 Added 56.37%	325,104 $9.19 Million
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $6.03 Million - $8.65 Million	207,912 New	207,912 $6.79 Million
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $2.69 Million - $5.05 Million	-164,857 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$7.95 - $18.81 $2.51 Million - $5.94 Million	-315,861 Reduced 65.71%	164,857 $2.69 Million
Q1 2020 May 14, 2020	SELL	$6.45 - $14.04 $961,108 - $2.09 Million	-149,009 Reduced 23.66%	480,718 $4.78 Million
Q4 2019 Feb 14, 2020	BUY	$12.97 - $15.94 $8.17 Million - $10 Million	629,727 New	629,727 $8.66 Million
Q3 2019 Nov 14, 2019	SELL	$14.75 - $20.87 $1.43 Million - $2.02 Million	-96,943 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $1.24 Million - $1.67 Million	84,421 Added 674.18%	96,943 $1.91 Million
Q1 2019 May 14, 2019	SELL	$13.73 - $16.87 $169,290 - $208,007	-12,330 Reduced 49.61%	12,522 $208,000
Q4 2018 Feb 14, 2019	SELL	$10.6 - $17.49 $4.42 Million - $7.29 Million	-417,095 Reduced 94.38%	24,852 $349,000
Q3 2018 Nov 14, 2018	SELL	$16.65 - $21.85 $1.38 Million - $1.81 Million	-82,925 Reduced 15.8%	441,947 $7.73 Million
Q2 2018 Aug 14, 2018	BUY	$14.8 - $18.8 $39,382 - $50,026	2,661 Added 0.51%	524,872 $9.55 Million
Q1 2018 May 15, 2018	BUY	$14.5 - $23.4 $3.17 Million - $5.11 Million	218,306 Added 71.83%	522,211 $9.79 Million
Q4 2017 Feb 14, 2018	BUY	$13.5 - $16.65 $1.08 Million - $1.33 Million	79,989 Added 35.72%	303,905 $4.65 Million
Q3 2017 Nov 14, 2017	BUY	$6.05 - $14.95 $1.35 Million - $3.35 Million	223,916	223,916 $3.35 Million

Others Institutions Holding KURA

# of Institutions

183

Shares Held

79.5M

Call Options Held

148K

Put Options Held

63K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $1.19B
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account